0001209191-21-029907.txt : 20210504 0001209191-21-029907.hdr.sgml : 20210504 20210504163530 ACCESSION NUMBER: 0001209191-21-029907 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210430 FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Priti CENTRAL INDEX KEY: 0001859997 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 21889109 MAIL ADDRESS: STREET 1: C/O NEOLEUKIN THERAPEUTICS, INC. STREET 2: 188 EAST BLAINE STREET, #450 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-30 0 0001404644 Neoleukin Therapeutics, Inc. NLTX 0001859997 Patel Priti C/O NEOLEUKIN THERAPEUTICS, INC. 188 EAST BLAINE STREET, #450 SEATTLE WA 98102 0 1 0 0 Chief Medical Officer Restricted Stock Units 0.00 2021-04-30 4 A 0 20000 0.00 A Common Stock 20000 20000 D Stock Option (Right to Buy) 12.49 2021-04-30 4 A 0 475000 0.00 A 2031-04-30 Common Stock 475000 475000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. The option vests as to 1/4 of the total shares on April 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Kris McGrew, as Attorney-in-Fact for Priti Patel 2021-05-04